Mithra Signs License and Supply Agreement with Mayne Pharma for Commercialization of Estelle in Australia

  • Consolidation of partnership with Mayne Pharma for commercialization of the combined oral contraceptive E4/DRSP (Estelle®) in Australia
  • Mithra eligible for milestone and license fees of up to EUR 3.5 million
  • Preparation ongoing for the commercial launch of Mithra’s oral contraceptive in the U.S. and Australia, targeted for H1 and H2 2021 respectively

Liege, Belgium, 28 May 2020 – 8:15 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces it has entered into an exclusive 20-year license and supply agreement with Mayne Pharma Group Limited (“Mayne”) for the commercialization of its combined oral contraceptive E4/DRSP (Estelle) in Australia.